A Controlled Clinical Study of Accelerated High-Dose Theta Burst Stimulation in Patients with Obsessive–Compulsive Disorder
Table 1
Baseline demographic and clinical characteristics of the participants.
Measures
ahTBS (n = 23)
rTMS (n = 22)
t/χ2
p
Mean ± SD
Mean ± SD
Sex (male/female)
16/7
10/12
2.68
0.10b
Age (years)
26.61 (6.99)
27.77 (7.50)
−0.54a
0.59
Education (years)
13.43 (2.17)
13.82 (2.75)
−0.52a
0.61
Duration of illness (years)
4.48 (4.91)
3.18 (4.82)
0.89a
0.38
Symptom estimations
Y-BOCS total
23.13 (6.68)
25.41 (5.12)
−1.28a
0.21
Y-BOCS obsession
13.13 (2.62)
13.14 (2.93)
−0.01a
0.99
Y-BOCS compulsion
10.00 (5.40)
12.27 (3.56)
−1.67a
0.10
OCI-R
23.09 (14.53)
23.68 (11.77)
−0.15a
0.88
HAMD
8.22 (4.63)
7.59 (5.31)
0.42a
0.68
HAMA
7.91 (5.61)
6.95 (5.10)
0.60a
0.55
Neuropsychological tests
TMT (B-A)
49.89 (39.67)
39.63 (16.29)
1.13a
0.27
SCWT (s)
12.69 (5.73)
11.12 (6.73)
0.84c
0.41c
DS forward
9.43 (1.65)
8.77 (0.97)
1.63a
0.11
DS backward
6.52 (1.59)
6.73 (1.64)
−0.43a
0.67
Medication status
Mean rank
Mean rank
Z
p
Fluoxetine equivalent (mg)
22.89
23.11
−0.06
0.96
Chlorpromazine equivalent (mg)
24.57
21.36
−0.88
0.38
Diazepam equivalent (mg)
19.52
26.64
−1.88
0.06
Note: Data are presented as mean (SD). Y-BOCS: Yale–Brown Obsessive–Compulsive Scale; HAMD: Hamilton Depression Scale; HAMA: Hamilton Anxiety Scale; OCI-R: obsessive–compulsive inventory-revised; TMT: trail making test; SCWT, Stroop color word test; DS: digit span. All antidepressant doses were converted to fluoxetine equivalents, all antipsychotic doses to chlorpromazine equivalents, and all sedative drug doses to diazepam equivalents. aPaired t-test. bFisher’s exact test. cOne patient in the ahTBS group did not take the test.
